Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s Lymphoma

뉴스 본문을 불러오고 있어요.

Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s Lymphoma | 웨이프 WAPE

Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s Lymphoma

기사 요약

관련 종목

댓글 —